[1]
|
Truby, L.K. and Rogers, J.G. (2020) Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. JACC: Heart Failure, 8, 523-536. https://doi.org/10.1016/j.jchf.2020.01.014
|
[2]
|
Metra, M. and Lucioli, P. (2020) Corrigendum to ‘Prevalence of Heart Failure and Left Ventricular Dysfunction in China: the China Hypertension Survey, 2012-2015’ [Eur J Heart Fail 2019; 21: 1329-1337]. European Journal of Heart Failure, 22, 759. https://doi.org/10.1002/ejhf.1808
|
[3]
|
国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组[J]. 2020中国心力衰竭医疗质量控制报告. 中国循环杂志, 2021, 36(3), 221-238.
|
[4]
|
Greene, S.J., Bauersachs, J., Brugts, J.J., et al. (2023) Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. Journal of the American College of Cardiology, 81, 413-424.
https://doi.org/10.1016/j.jacc.2022.11.023
|
[5]
|
McDonagh, T.A., Metra, M., Adamo, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726. https://doi.org/10.1093/eurheartj/ehab368
|
[6]
|
Shugg, T., Hudmon, A. and Overholser, B.R. (2020) Neurohormonal Regulation of I(Ks) in Heart Failure: Implications for Ventricular Arrhythmogenesis and Sudden Cardiac Death. Journal of the American Heart Association, 9, e016900.
https://doi.org/10.1161/JAHA.120.016900
|
[7]
|
Manolis, A.A., Manolis, T.A. and Manolis, A.S. (2023) Neuro-humoral Activation in Heart Failure. International Journal of Molecular Sciences, 24, Article 15472. https://doi.org/10.3390/ijms242015472
|
[8]
|
Usman, M.S., Siddiqi, T.J., Anker, S.D., et al. (2023) Effect of SGLT2 Inhibitors on Cardiovascular Outcomes across Various Patient Populations. Journal of the American College of Cardiology, 81, 2377-2387.
https://doi.org/10.1016/j.jacc.2023.04.034
|
[9]
|
McMurray, J., Solomon, S.D., Inzucchi, S.., et al. (2019) Dapagli-flozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine, 381, 1995-2008. https://doi.org/10.1056/NEJMoa1911303
|
[10]
|
Vaduganathan, M., Docherty, K.F., Claggett, B.L., et al. (2022) SGLT-2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Con-trolled Trials. The Lancet, 400, 757-767.
https://doi.org/10.1016/S0140-6736(22)01429-5
|
[11]
|
Scheen, A.J. (2019) Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Current Cardiology Reports, 21, Article No. 70. https://doi.org/10.1007/s11886-019-1165-1
|
[12]
|
Shimizu, W., Kubota, Y., Hoshika, Y., et al. (2020) Effects of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Di-abetes Mellitus: the EMBODY Trial. Cardiovascular Diabetology, 19, Article No. 148. https://doi.org/10.1186/s12933-020-01127-z
|
[13]
|
Chiba, Y., Sugiyama, Y., Nishi, N., et al. (2020) Sodi-um/Glucose Cotransporter 2 Is Expressed in Choroid Plexus Epithelial Cells and Ependymal Cells in Human and Mouse Brains. Neuropathology, 40, 482-491.
https://doi.org/10.1111/neup.12665
|
[14]
|
Abbott, N.J., Patabendige, A.A., Dolman, D.E., et al. (2010) Structure and Function of the Blood-Brain Barrier. Neurobiology of Disease, 37, 13-25. https://doi.org/10.1016/j.nbd.2009.07.030
|
[15]
|
Nguyen, T., Wen, S., Gong, M., et al. (2020) Dapagliflozin Acti-vates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice. Di-abetes, Metabolic Syndrome and Obesity, 13, 2781-2799. https://doi.org/10.2147/DMSO.S258593
|
[16]
|
Amin, E.F., Rifaai, R.A. and Abdel-Latif, R.G. (2020) Empagliflozin Attenuates Transient Cerebral Ischemia/Reperfusion Injury in Hyperglycemic Rats via Repressing Oxidative-Inflammatory-Apoptotic Pathway. Fundamental & Clinical Pharma-cology, 34, 548-558. https://doi.org/10.1111/fcp.12548
|
[17]
|
Zhang, Y., Wen, W. and Liu, H. (2020) the Role of Immune Cells in Cardiac Remodeling after Myocardial Infarction. Journal of Cardiovascular Pharmacology, 76, 407-413. https://doi.org/10.1097/FJC.0000000000000876
|
[18]
|
Koyani, C.N., Plastira, I., Sourij, H., et al. (2020) Empagliflozin Protects Heart from Inflammation and Energy Depletion via AMPK Activation. Pharmacological Re-search, 158, Article ID: 104870.
https://doi.org/10.1016/j.phrs.2020.104870
|
[19]
|
Byrne, N.J., Matsumura, N., Maayah, Z.H., et al. (2020) Empagli-flozin Blunts Worsening Cardiac Dysfunction Associated with Reduced NLRP3 (Nucleotide-Binding Domain-Like Re-ceptor Protein 3) Inflammasome Activation in Heart Failure. Circulation: Heart Failure, 13, e006277. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006277
|
[20]
|
Kim, S.R., Lee, S.G., Kim, S.H., et al. (2020) SGLT2 Inhibition Modulates NLRP3 Inflammasome Activity via Ketones and Insulin in Diabetes with Cardiovascular Disease. Nature Communications, 11, Article No. 2127.
https://doi.org/10.1038/s41467-020-15983-6
|
[21]
|
孙帅锋, 刘巍. 心肌纤维化病理机制及诊疗策略进展[J]. 国际心血管病杂志, 2020, 47(5), 264-267.
|
[22]
|
Santos-Gallego, C.G., Requena-Ibanez, J.A., San, A.R., et al. (2021) Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC: Cardiovascular Imaging, 14, 393-407. https://doi.org/10.1016/j.jcmg.2020.07.042
|
[23]
|
Lee, T.M., Chang, N.C. and Lin, S.Z. (2017) Dapagliflozin, a Se-lective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts. Free Radical Biology and Medicine, 104, 298-310. https://doi.org/10.1016/j.freeradbiomed.2017.01.035
|
[24]
|
Tkaczyszyn, M., Górniak, K.M., Lis, W.H., et al. (2022) Iron Deficiency and Deranged Myocardial Energetics in Heart Failure. International Journal of Environmental Research and Public Health, 19, Article 17000.
https://doi.org/10.3390/ijerph192417000
|
[25]
|
Santos-Gallego, C.G., Requena-Ibanez, J.A., San, A.R., et al. (2019) Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 73, 1931-1944. https://doi.org/10.1016/j.jacc.2019.01.056
|
[26]
|
Oh, C.M., Cho, S., Jang, J.Y., et al. (2019) Cardioprotective Poten-tial of an SGLT2 Inhibitor against Doxorubicin-Induced Heart Failure. Korean Circulation Journal, 49, 1183-1195. https://doi.org/10.4070/kcj.2019.0180
|